The Relation of Diabetes Complications to a New Interpretation of Glycaemic Variability from Continuous Glucose Monitoring in People with Type 1 Diabetes.

Complications Continuous glucose monitoring Glycaemic variability Hyperglycaemia Type 1 diabetes

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
23 Oct 2024
Historique:
received: 20 06 2024
accepted: 30 08 2024
medline: 24 10 2024
pubmed: 24 10 2024
entrez: 23 10 2024
Statut: aheadofprint

Résumé

Microvascular and macrovascular complications in type 1 diabetes (T1D) may be linked to endothelial stress due to glycaemic variability. Continuous glucose monitoring systems (CGMs) provide new opportunities to quantify this variability, utilising the amplitude of glucose change summated over time. The aim of this study was to examine whether this determination of glucose variability (GV) is associated with microvascular clinical sequelae. Continuous glucose monitoring values were downloaded for 89 type 1 diabetes mellitus (T1D) individuals for up to 18 months from 2021 to 2023. Data for patient demographics was also taken from the patient record which included Sex, Date of Birth, and Date of Diagnosis. The recorded laboratory glycated haemoglobin (HbA1c) test results were also recorded. The glucose management index (GMI) was calculated from average glucose readings for 18 months using the formula GMI (%) = (0.82-(Average glucose/100)). This was then adjusted to give GMI (mmol/mol) = 10.929 * (GMI (%) - 2.15). Average Glucose Fluctuation (AGF) was calculated by adding up the total absolute change value between all recorded results over 18 months and dividing by the number of results minus one. The % Above Critical Threshold (ACT) was calculated by summing the total number of occurrences for each result value. A cumulative 95% limit was then applied to identify the glucose value that only 5% of results exceeded in the overall population. Using this value, we estimated the percentage of total tests that were above the Critical Threshold (ACT). Results for the 89 individuals (44 men and 45 women) were analysed over 18 months. The mean age of participants was 43 years and the mean duration of diabetes was 18 years. A total of 3.22 million readings were analysed, giving an average of 10.3 mmol/L blood glucose. Those with the largest change in glucose from reading to reading, summated over time, showed the greatest change in eGFR of 3.12 ml/min/1.73 m Those individuals with T1D in the highest tertile of reading-to-reading glucose change showed the greatest change in eGFR. Those with a higher proportion of glucose readings > 18 mmol/L also showed a fall in eGFR and experienced higher rates of sight-threatening retinopathy, as did people with higher mean glucose. Discussions with T1D individuals could reflect on how the percentage recorded glucose above a critical level and degree of change in glucose are important in avoiding future tissue complications.

Identifiants

pubmed: 39443335
doi: 10.1007/s13300-024-01648-w
pii: 10.1007/s13300-024-01648-w
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

© 2024. The Author(s).

Références

Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Survival, causes of death, and complications. Diabetologia. 1978;14(6):363–70.
doi: 10.1007/BF01228130 pubmed: 669100
Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–53.
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40:994–9.
doi: 10.2337/dc17-0636 pubmed: 28733374 pmcid: 5521971
Heinemann L, Freckmann G, Müller-Wieland D, Kellerer M. Critical reappraisal of the time-in-range: alternative or useful addition to glycated hemoglobin? J Diabetes Sci Technol. 2020;14(5):922–7.
doi: 10.1177/1932296819883885 pubmed: 31675907
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968–83.
doi: 10.2337/diab.44.8.968
Kilpatrick ES, Rigby AS, Atkin SL. Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care. 2009;32(10):1901–3.
doi: 10.2337/dc09-0109 pubmed: 19549736 pmcid: 2752912
FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973–81.
doi: 10.2337/dc15-2782
FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care. 2016;39:973–81.
doi: 10.2337/dc15-2782
Suh S, Kim JH. Glycemic variability: how do we measure it and why is it important? Diabetes Metab J. 2015;39:273–82.
doi: 10.4093/dmj.2015.39.4.273 pubmed: 26301188 pmcid: 4543190
Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013;15(Suppl 2):3–8.
doi: 10.1111/dom.12140 pubmed: 24034513
Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387(16):1477–87.
Bergenstal RM, Beck RW, Close KL, et al. Glucose Management Indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–80.
doi: 10.2337/dc18-1581 pubmed: 30224348 pmcid: 6196826
Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.
doi: 10.1161/CIRCRESAHA.110.223545 pubmed: 21030723 pmcid: 2996922
Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52(11):2795–804.
doi: 10.2337/diabetes.52.11.2795 pubmed: 14578299
Skol AD, Jung SC, Sokovic AM, et al. Integration of genomics and transcriptomics predicts diabetic retinopathy susceptibility genes. Elife. 2020;9:e59980.
doi: 10.7554/eLife.59980 pubmed: 33164750 pmcid: 7728435
Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370–6.
doi: 10.2337/dc18-1131 pubmed: 30201847
Zinman B, Marso SP, Poulter NR, et al. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:48–57.
doi: 10.1007/s00125-017-4423-z pubmed: 28913575
Pieber TR, Marso SP, McGuire DK, on behalf of the DEVOTE StudGroup, et al. DEVOy TE3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61:58–65.
doi: 10.1007/s00125-017-4422-0 pubmed: 28913543
Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
doi: 10.1056/NEJM199309303291401 pubmed: 8366922
Zhou JJ, Coleman R, Holman RR, Reaven P. Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. Diabetologia. 2020;63(11):2482–5.
doi: 10.1007/s00125-020-05273-7 pubmed: 32954444 pmcid: 7573923
Scott E, Januszewski A, O’Connell R, et al. Long-term glycaemic variability and vascular complications in Type 2 diabetes: post-hoc analysis of the FIELD study. J Clin Endocrinol Metab. 2020;105(10):e3638–49.
doi: 10.1210/clinem/dgaa361
Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34:612–6.
doi: 10.1016/j.diabet.2008.04.005 pubmed: 18824382
The DECODE study group on behalf of the Europe an Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:P617–21.
DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomized controlled trial. BMJ. 2002;325(7367):746. https://doi.org/10.1136/bmj.325.7367.746 .
doi: 10.1136/bmj.325.7367.746 pmcid: 128375
https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2019/07/dia-FreeStyle-Libre-training-pack-for-HCP-and-patients-052018.pdf . Accessed 30 April 2024
Livingstone R, Boyle JG, Petrie JR. How tightly controlled do fluctuations in blood glucose levels need to be to reduce the risk of developing complications in people with Type 1 diabetes? Diabet Med. 2020;37:513–21.
doi: 10.1111/dme.13911 pubmed: 30697804

Auteurs

Adrian H Heald (AH)

The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK. adrian.heald@manchester.ac.uk.
Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, M6 8HD, UK. adrian.heald@manchester.ac.uk.

Mike Stedman (M)

Res Consortium Ltd., Andover, UK.

John Warner Levy (JW)

The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.

Lleyton Belston (L)

The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.

Angela Paisley (A)

Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, M6 8HD, UK.

Reena Patel (R)

Spinney Hill Medical Centre, Leicester, UK.

Alison White (A)

Middlewood Primary Care Group, Cheshire, UK.

Edward Jude (E)

Department of Diabetes, Tameside General Hospital, Greater Manchester, UK.

JMartin Gibson (J)

The School of Medicine, Manchester Academic Health Sciences Centre, Manchester University, Manchester, UK.
Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, M6 8HD, UK.

Hellena Habte-Asres (H)

Department of Diabetes, Kings College Hospital, London, UK.

Martin Whyte (M)

Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.

Angus Forbes (A)

Department of Diabetes, King's College London, London, UK.

Classifications MeSH